{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:26Z","timestamp":1789750286374,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shandong Provincial Medical and Health Science and Technology Projects","award":["202511000079"],"award-info":[{"award-number":["202511000079"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation Project","doi-asserted-by":"publisher","award":["ZR2021MH214"],"award-info":[{"award-number":["ZR2021MH214"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jinan Clinical Medical Science and Technology Innovation Plan Project","award":["202134029"],"award-info":[{"award-number":["202134029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the reliability of different antimicrobial-susceptibility testing methods for determining the susceptibility of Staphylococcus aureus to eravacycline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using broth microdilution (BMD) as the reference method, disk diffusion (DD) and MIC test strips (MTS) were employed to test 422 S. aureus isolates (256 MSSA and 166 MRSA). Interpretive breakpoints for eravacycline followed the ChinaCAST criteria (MIC \u2264 0.25\u2005mg\/L or inhibition zone diameter \u2265 20\u2005mm\u200a=\u200asusceptible). BMD results were used to calculate categorical agreement (CA), essential agreement (EA), major errors (ME), and very major errors (VME) for each comparator method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The susceptibility rates to eravacycline were 93.6% (BMD), 96.9% (MTS) and 93.1% (DD). Compared with BMD, MTS yielded CA 96.7%, EA 63.0% and VME 3.3%, whereas DD showed CA 98.1%, ME 1.2% and VME 0.7%. Stratified analysis revealed that MRSA was the main source of VME (7.8% for MTS and 1.8% for DD). Disk diffusion showed excellent agreement with BMD (\u03ba\u200a=\u200a0.85, 95% CI 0.74\u20130.95), whereas MTS yielded good agreement (\u03ba = 0.64, 95% CI 0.46\u20130.81).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Under the conditions of this study, disk diffusion demonstrated excellent categorical agreement with BMD and can serve as an alternative method for routine laboratory detection of eravacycline susceptibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf502","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:03:10Z","timestamp":1766581390000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422\n                    <i>Staphylococcus aureus<\/i>\n                    isolates using ChinaCAST breakpoints"],"prefix":"10.1093","volume":"81","author":[{"given":"Xinying","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]},{"name":"Shandong Provincial Key Medical and Health Laboratory of Anti-Drug Resistant Drug Research, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunlu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]},{"name":"Department of Brain Injury Laboratory, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital , Jinan 250022 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]},{"name":"Department of Brain Injury Laboratory, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-2356","authenticated-orcid":false,"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]},{"name":"Shandong Provincial Key Medical and Health Laboratory of Anti-Drug Resistant Drug Research, The Affiliated Taian City Central Hospital of Qingdao University , Taian 271000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902093421500_dkaf502-B1","doi-asserted-by":"publisher","first-page":"8182","DOI":"10.3390\/ijms24098182","article-title":"Staphylococcus aureus infection: pathogenesis and antimicrobial resistance","volume":"24","author":"Gherardi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026011902093421500_dkaf502-B2","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.lanmic.2024.07.003","article-title":"WHO publishes updated list of bacterial priority pathogens","volume":"5","author":"Jesudason","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026011902093421500_dkaf502-B3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of Staphylococcus aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"key":"2026011902093421500_dkaf502-B4","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2666-5247(24)00040-5","article-title":"Staphylococcus aureus colonisation and strategies for decolonisation","volume":"5","author":"Piewngam","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026011902093421500_dkaf502-B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jinf.2022.10.042","article-title":"Redefining Staphylococcus aureus bacteremia: a structured approach guiding diagnostic and therapeutic management","volume":"86","author":"Kouijzer","year":"2023","journal-title":"J Infect"},{"key":"2026011902093421500_dkaf502-B6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA"},{"key":"2026011902093421500_dkaf502-B7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2026011902093421500_dkaf502-B8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12866-020-01869-6","article-title":"Eravacycline susceptibility was impacted by genetic mutation of 30S ribosome subunits, and branched-chain amino acid transport system II carrier protein, Na\/Pi cotransporter family protein in Staphylococcus aureus","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Microbiol"},{"key":"2026011902093421500_dkaf502-B9","author":"China Antimicrobial Surveillance Network"},{"key":"2026011902093421500_dkaf502-B10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/antibiotics12030455","article-title":"Persistent methicillin-resistant Staphylococcus aureus bacteraemia: host, pathogen, and treatment","volume":"12","author":"Parsons","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011902093421500_dkaf502-B11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"2026011902093421500_dkaf502-B12","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026011902093421500_dkaf502-B13","doi-asserted-by":"publisher","first-page":"e0165022","DOI":"10.1128\/jcm.01650-22","article-title":"Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and Enterococci","volume":"61","author":"Blanchard","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026011902093421500_dkaf502-B14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cmi.2025.04.014","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for eravacycline susceptibility testing","volume":"31","author":"Yang","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093421500_dkaf502-B15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2026011902093421500_dkaf502-B16","doi-asserted-by":"publisher","first-page":"e0171522","DOI":"10.1128\/spectrum.01715-22","article-title":"Activities of eravacycline, tedizolid, norvancomycin, nemonoxacin, ceftaroline and comparators against 1,871 Staphylococcus and 1,068 Enterococcus spp. isolates from China: updated report of the CHINET study 2019","volume":"10","author":"Ding","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026011902093421500_dkaf502-B17","doi-asserted-by":"publisher","first-page":"e01715-19","DOI":"10.1128\/AAC.01715-19","article-title":"In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093421500_dkaf502-B18","doi-asserted-by":"publisher","first-page":"1504013","DOI":"10.3389\/fmicb.2024.1504013","article-title":"In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China","volume":"15","author":"Liao","year":"2024","journal-title":"Front Microbiol"},{"key":"2026011902093421500_dkaf502-B19","doi-asserted-by":"publisher","first-page":"e0235123","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022","volume":"12","author":"Kunz Coyne","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026011902093421500_dkaf502-B20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.cn114452-20250211-00074","article-title":"In vitro susceptibility testing standard for eravacycline","volume":"48","author":"National Committee for Clinical Laboratory Standards of China","year":"2025","journal-title":"Chin J Lab Med"},{"key":"2026011902093421500_dkaf502-B21","author":"CLSI"},{"key":"2026011902093421500_dkaf502-B22","author":"CLSI"},{"key":"2026011902093421500_dkaf502-B23","author":"CLSI"},{"key":"2026011902093421500_dkaf502-B24","author":"CLSI"},{"key":"2026011902093421500_dkaf502-B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","article-title":"Value of hospital antimicrobial stewardship programmes [ASPs]: a systematic review","volume":"8","author":"Nathwani","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026011902093421500_dkaf502-B26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41579-020-0327-x","article-title":"Innovative and rapid antimicrobial susceptibility testing systems","volume":"18","author":"Van Belkum","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2026011902093421500_dkaf502-B27","doi-asserted-by":"publisher","first-page":"1043736","DOI":"10.3389\/fmicb.2022.1043736","article-title":"In vitro antimicrobial activity and resistance mechanisms of the new-generation tetracycline agents eravacycline, omadacycline and tigecycline against clinical Staphylococcus aureus isolates","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Microbiol"},{"key":"2026011902093421500_dkaf502-B28","doi-asserted-by":"publisher","first-page":"e01304-20","DOI":"10.1128\/AAC.01304-20","article-title":"Planktonic and biofilm activity of eravacycline against Staphylococci isolated from periprosthetic joint infections","volume":"64","author":"Zhuchenko","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf502\/66444091\/dkaf502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf502\/66444091\/dkaf502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:39Z","timestamp":1768806579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf502\/8429088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf502","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf502"}}